92 related articles for article (PubMed ID: 16112616)
1. Diminished neo-antigen response to keyhole limpet hemocyanin (KLH) vaccines in patients after treatment with chemotherapy or hematopoietic cell transplantation.
Miller JS; Curtsinger J; Berthold M; Malvey K; Bliss RL; Le CT; Fautsch SK; Dudek AZ; Blazar BR; Panoskaltsis-Mortari A
Clin Immunol; 2005 Nov; 117(2):144-51. PubMed ID: 16112616
[TBL] [Abstract][Full Text] [Related]
2. Potential of dendritic-cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyhole-limpet-hemocyanin-pulsed, donor-derived dendritic-cell vaccine for acute myeloid leukemia.
Kitawaki T; Kadowaki N; Kondo T; Ishikawa T; Ichinohe T; Teramukai S; Fukushima M; Kasai Y; Maekawa T; Uchiyama T
Am J Hematol; 2008 Apr; 83(4):315-7. PubMed ID: 18081032
[TBL] [Abstract][Full Text] [Related]
3. Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.
Schmittling RJ; Archer GE; Mitchell DA; Heimberger A; Pegram C; Herndon JE; Friedman HS; Bigner DD; Sampson JH
J Immunol Methods; 2008 Nov; 339(1):74-81. PubMed ID: 18775433
[TBL] [Abstract][Full Text] [Related]
4. Antibody response to keyhole limpet hemocyanin (KLH) treatment in patients with superficial bladder carcinoma.
Jurincic-Winkler CD; von der Kammer H; Beuth J; Scheit KH; Klippel KF
Anticancer Res; 1996; 16(4A):2105-10. PubMed ID: 8712751
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine.
Holmberg LA; Oparin DV; Gooley T; Lilleby K; Bensinger W; Reddish MA; MacLean GD; Longenecker BM; Sandmaier BM
Bone Marrow Transplant; 2000 Jun; 25(12):1233-41. PubMed ID: 10871727
[TBL] [Abstract][Full Text] [Related]
6. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.
Slovin SF; Ragupathi G; Musselli C; Fernandez C; Diani M; Verbel D; Danishefsky S; Livingston P; Scher HI
Cancer Immunol Immunother; 2005 Jul; 54(7):694-702. PubMed ID: 15726361
[TBL] [Abstract][Full Text] [Related]
7. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.
Ragupathi G; Livingston PO; Hood C; Gathuru J; Krown SE; Chapman PB; Wolchok JD; Williams LJ; Oldfield RC; Hwu WJ
Clin Cancer Res; 2003 Nov; 9(14):5214-20. PubMed ID: 14614001
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients.
Lesterhuis WJ; De Vries IJ; Schreibelt G; Schuurhuis DH; Aarntzen EH; De Boer A; Scharenborg NM; Van De Rakt M; Hesselink EJ; Figdor CG; Adema GJ; Punt CJ
Anticancer Res; 2010 Dec; 30(12):5091-7. PubMed ID: 21187495
[TBL] [Abstract][Full Text] [Related]
9. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21.
Gilewski T; Adluri S; Ragupathi G; Zhang S; Yao TJ; Panageas K; Moynahan M; Houghton A; Norton L; Livingston PO
Clin Cancer Res; 2000 May; 6(5):1693-701. PubMed ID: 10815887
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients.
Hobo W; Strobbe L; Maas F; Fredrix H; Greupink-Draaisma A; Esendam B; de Witte T; Preijers F; Levenga H; van Rees B; Raymakers R; Schaap N; Dolstra H
Cancer Immunol Immunother; 2013 Aug; 62(8):1381-92. PubMed ID: 23728352
[TBL] [Abstract][Full Text] [Related]
11. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
[TBL] [Abstract][Full Text] [Related]
12. Modulation of systemic antigen-specific immune responses by oral antigen in humans.
Kapp K; Maul J; Hostmann A; Mundt P; Preiss JC; Wenzel A; Thiel A; Zeitz M; Ullrich R; Duchmann R
Eur J Immunol; 2010 Nov; 40(11):3128-37. PubMed ID: 20957752
[TBL] [Abstract][Full Text] [Related]
13. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.
Lesterhuis WJ; de Vries IJ; Schreibelt G; Lambeck AJ; Aarntzen EH; Jacobs JF; Scharenborg NM; van de Rakt MW; de Boer AJ; Croockewit S; van Rossum MM; Mus R; Oyen WJ; Boerman OC; Lucas S; Adema GJ; Punt CJ; Figdor CG
Clin Cancer Res; 2011 Sep; 17(17):5725-35. PubMed ID: 21771874
[TBL] [Abstract][Full Text] [Related]
14. Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells.
Reichardt VL; Milazzo C; Brugger W; Einsele H; Kanz L; Brossart P
Haematologica; 2003 Oct; 88(10):1139-49. PubMed ID: 14555310
[TBL] [Abstract][Full Text] [Related]
15. Preexisting antigen-specific immune responses are modulated by oral KLH feeding in humans.
Hostmann A; Meyer T; Maul J; Preiss J; Boortz B; Thiel A; Duchmann R; Ullrich R
Eur J Immunol; 2015 Jul; 45(7):1991-6. PubMed ID: 25847325
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer.
Chang AE; Redman BG; Whitfield JR; Nickoloff BJ; Braun TM; Lee PP; Geiger JD; Mulé JJ
Clin Cancer Res; 2002 Apr; 8(4):1021-32. PubMed ID: 11948109
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer.
Dickler MN; Ragupathi G; Liu NX; Musselli C; Martino DJ; Miller VA; Kris MG; Brezicka FT; Livingston PO; Grant SC
Clin Cancer Res; 1999 Oct; 5(10):2773-9. PubMed ID: 10537341
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors.
Heimberger AB; Crotty LE; Archer GE; Hess KR; Wikstrand CJ; Friedman AH; Friedman HS; Bigner DD; Sampson JH
Clin Cancer Res; 2003 Sep; 9(11):4247-54. PubMed ID: 14519652
[TBL] [Abstract][Full Text] [Related]
19. Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells.
Röllig C; Schmidt C; Bornhäuser M; Ehninger G; Schmitz M; Auffermann-Gretzinger S
J Immunother; 2011 Jan; 34(1):100-6. PubMed ID: 21150718
[TBL] [Abstract][Full Text] [Related]
20. A cancer vaccine based on fluorine-modified sialyl-Tn induces robust immune responses in a murine model.
Song C; Zheng XJ; Liu CC; Zhou Y; Ye XS
Oncotarget; 2017 Jul; 8(29):47330-47343. PubMed ID: 28537884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]